Goldman Sachs upgrades BioNTech to buy, sees stock surging more than 25%

The bank upgraded shares of the German biotechnology firm to a buy rating from neutral.

Nov 8, 2024 - 18:30
 0  0
Goldman Sachs upgrades BioNTech to buy, sees stock surging more than 25%
The bank upgraded shares of the German biotechnology firm to a buy rating from neutral.